Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy

Allergy and Asthma Proceedings

Volumn 26, Issue 5, 2005, Pages 327-335

  Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

ASTHMA; CONFERENCE PAPER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ASTHMA; GLUCOCORTICOIDS; HUMANS; TREATMENT OUTCOME;

EID: 27644565757     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Tashkin D. The role of small airway inflammation in asthma. Allergy Asthma Proc 23:233-242, 2002.
2. Leung D, and Bloom J. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111:1-20, 2003.
3. Howarth P. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med 14(suppl 1):S27-S34, 2001.
4. Suissa S, Ernst P, and Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 57:880-884, 2002.
5. Apter AJ. Clinical advances in adult asthma. J Allergy Clin Immunol 111(suppl 3):S780-S784, 2003.
6. Toogood J. Side effects of inhaled corticosteroids. J Allergy Clin Immunol 102:705-713, 1998.
7. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:440-446, 1998.
8. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91(suppl A):22-28, 1997.
9. Boobis A. Comparative physiochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respir Med 92(suppl B):2-6, 1998.
10. Kelly H. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am 5:537-553, 1999.
11. Dietzel K, Engelstatter R, and Keller A. Ciclesonide: An on-site-activated steroid. In New Drugs for Asthma, Allergy, and COPD, Vol. 31. Hansel T, and Barnes P (Eds). Basel: Karger, 91-93, 2001.
12. Daley-Yates P, Price A, Sisson J, et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics, and metabolism following intravenous, oral, intranasal, and inhaled administration in man. Br J Clin Pharmacol 51:400-409, 2001.
13. Newman S. Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 42:529-544, 2003.
14. Thorsson L, Edsbacker S, and Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J 7:1839-1844, 1994.
15. Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 63:86-95, 1982.
16. Dickens G, Wermeling D, Matheny C, et al. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol 84:528-532, 2000.
17. Thorsson L, Dahlstrom K, Edsbacker A, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 43:155-161, 1997.
18. Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 53:459-467, 1998.
19. Nave R, Bethke T, van Marle S, and Zech K. Pharmacokinetics of 14C-ciclesonide after oral and intravenous administration in healthy subjects. In European Respiratory Society Annual Congress 2002. Stockholm, Sweden, 2002, ERS Journals Ltd., Sheffield, UK.
20. Nave R, Drollmann A, Bethke T, et al. Repeated daily inhalations of ciclesonide, compared to single inhalation do not lead to increased systemic exposure. In European Respiratory Society Annual Congress 2003. Vienna, Austria, 2003 ERS Journals Ltd., Sheffield, UK.
21. Affrime M, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 40:1227-1236, 2000.
22. Derendorf H, Daley-Yates P, and Pierre L. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J Clin Pharmacol 42:383-387, 2002.
23. Crim C, Pierre L, and Daley-Yates P, et al. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 23:1339-1354, 2001.
24. Brocklebank D, Wright J, and Cates C. National Health Technology Assessment Inhaler Review Group. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Br Med J 323:1-7, 2001.
25. Lipworth B, and Jackson C. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium. Drug Safety 23:11-33, 2000.
26. Leach C, Davidson P, and Boudreau R. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 12:1346-1353, 1998.
27. Leach C. Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 104:S250-S252, 1999.
28. Donaldson K, Li X, and MacNee W. Ultrafine (nanometer) particle mediated lung injury. J Aerosol Sci 29:553-560, 1998.
29. Oberdorster G. Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health 74:1-8, 2001.
30. Bethke T, Boudreau R, Hasselquist B, et al. High lung deposition of ciclesonide in 2D and 3D imaging. In European Respiratory Society Annual Meeting 2002. Stockholm, Sweden, 2002, ERS Journals Ltd., Sheffield, UK.
31. Weinbrenner A, Hüneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 87:2160-2163, 2002.
32. Rowland M, and Tozer T. Intravenous Dose. In Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, PA: Williams & Wilkins, 1995, p. 24.
33. Mackie A, Ventresca G, Fuller R, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 41:539-542, 1996.
34. Nave R, Fisher R, and Zech K. In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. In American Thoracic Society 99th International Conference. Seattle, WA, 2003, American Thoracic Society Pub, NY, NY.
35. Nave R, Sattele N, Meyer W, et al. Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. In American Thoracic Society 99th International Conference. Seattle, Washington, 2003 American Thoracic Society Pub, NY, NY.
36. Nave R, Bethke T, Seiberling M, et al. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. In European Respiratory Society Annual Congress 2002. Stockholm, Sweden, 2002, ERS Journals Ltd., Sheffield, UK.
37. Rohatagi S, Derendorf H, Zech K, et al. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide. In The 60th Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, Denver, CO, 2003, Pub, AAAAI, Milwaukee, WI.
38. Tunek A, Sjodin K, and Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung, and liver microsomes. Drug Metab Dispos 25:1311-1317, 1997.
39. Edsbacker S, and Brattsand R. Budesonide fatty-acid esterification: A novel mechanism prolonging binding to ariway tissue. Review of available data. Ann Allergy Asthma Immunol 88:609-616, 2002.
40. Miller-Larsson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide: Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 26:623-630, 1998.
41. Szefler S. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol 108(suppl 1): S26-S31, 2001.
42. Martin L, Harrison C, and Tanner R. Metabolism of beclomethasone dipropionate by animals and man. Postgrad Med J 51(suppl 4):11-20, 1975.
43. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43:365-378, 2003.
44. Benet L, and Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121, 2002.
45. Hanania N, Chapman K, and Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 98:196-208, 1995.
46. Derendorf H, Mollmann H, Hochhaus G, et al. Clinical PK/PD modelling as a tool in drug development of corticosteroids. Int J Clin Pharmacol Ther 35:481-488, 1997.
47. Tinkelman D, Reed C, Nelson H, et al. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 92:64-77, 1993.
48. Meibohm B, Hochhaus G, Mollmann H, et al. A pharmacokinetic/ pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm 27:127-47, 1999.
49. Wald J, and Jusko W. Corticosteroid pharmacodynamic modeling: Osteocalcin suppression by prednisolone. Pharm Res 9:1096-1098, 1992.
50. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 159:941-955, 1999.
51. Affrime M, Kosoglow T, Thonoor C, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 118:1538-1546, 2000.
52. Derom E, Velde VVD, Marissens S, et al. Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients. In The European Respiratory Society Annual Congress. Berlin, 2001, ERS Journals Ltd., Sheffield, UK.
53. Pauwels R, Derom E, van der Velde V, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [abstract]. In American Thoracic Society 98th International Conference, Atlanta, GA, 2002.